India Introduces New Vaccine Tools To Strengthen Fight Against Tuberculosis

India’s long-standing battle against Tuberculosis (TB) is entering a new phase, with the introduction of two potential new vaccine tools developed by Cadila Pharmaceuticals Ltd and the Serum Institute of India. The vaccines, while not a definitive solution to the disease, represent a significant step forward in strengthening prevention strategies in a country that carries the world’s largest TB burden.

Tuberculosis remains one of the deadliest infectious diseases globally, and India accounts for roughly one-quarter of all cases worldwide. According to international estimates, millions continue to fall ill each year, with India recording a substantial share of both new infections and deaths. Despite improvements in diagnosis and treatment under the National Tuberculosis Elimination Programme, the disease continues to affect large populations, particularly working-age adults and vulnerable communities.

The newly studied vaccines have been evaluated through a large, independent Phase III clinical trial led, funded, and sponsored by the Indian Council of Medical Research (ICMR). The trial involved more than 12,700 participants across 18 sites in six Indian states, focusing on household contacts of TB patients and individuals with risk factors. The findings have been published in The British Medical Journal (BMJ), adding international scientific validation to the results.

Also Read: Strengthen Bones With These 9 Non-Dairy Calcium-Rich Drinks

Experts note that while neither vaccine showed strong overall protection against all forms of tuberculosis, one of the candidates, VPM1002, demonstrated about 50 percent efficacy against extra-pulmonary TB, a form of the disease that affects organs beyond the lungs and is often harder to diagnose and treat. Both vaccines also showed stronger effects in specific groups, including children and individuals with latent TB infection, suggesting potential use in targeted prevention strategies.

The significance of these findings lies in the limitations of the century-old BCG vaccine, which provides strong protection in infants but limited long-term protection in adolescents and adults, where TB transmission is highest. Health experts say even partial protection—especially against severe and extra-pulmonary disease—could reduce deaths, disability, and healthcare costs, while complementing existing treatment and control measures.

While researchers caution that these vaccines are not a “magic bullet,” they are being seen as an important scientific advance in India’s TB elimination efforts. With further regulatory approvals and policy support, the low projected cost of production could make large-scale preventive vaccination feasible, potentially strengthening India’s long-term strategy to curb and eventually eliminate tuberculosis.

Also Read: Study Shows Video Games can Bridge Health Literacy Gaps with Digital Game Design